Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Febuxostat 80 mg bioequivalence study in healthy Thai volunteers under fasting conditions
TCTR20230426005Phase 1Unknown
- Sponsor
- Bio-innova
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of febuxostat in hyperuricemia (3 arms), sponsored by Bio-innova. Primary endpoints: Cmax at 36.00 hours, AUC0-t at 36.00 hours and 1 more. Status: unknown.
02
Drugs
febuxostat
03
Conditions
hyperuricemia
Beyond the preview
Go deeper on TCTR20230426005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20230426005.